CD34+ Cell Targeted Antibody-Conjugated Premade Empty Lipid Nanoparticle

The CD34+ Cell Targeted Empty Premade Antibody-Conjugated Lipid Nanoparticle Kit provides a sophisticated negative control solution for targeted delivery studies to T cells. This innovative formulation features lipid nanoparticles (LNPs) decorated with anti-human CD34 antibody monoclonal antibody, specifically engineered to enhance targeting efficiency to CD34 positive cells without any therapeutic payload. The antibody is covalently conjugated to lipid molecules to achieve optimal targeting effects while maintaining the same delivery characteristics as payload-containing formulations.

This advanced empty delivery system utilizes SM102 as the main ionizable lipid and serves as an essential control for experiments involving targeted mRNA or drug delivery to CD34+ T cells. The formulation demonstrates enhanced delivery specificity to CD34+ T cells, making it an invaluable tool for validating targeting specificity and assessing baseline cellular responses.

Key Features

Targeted Control System: Anti-human CD34 antibody conjugation for specific CD34+ T cell targeting without payload interference
Identical Targeting Properties: Same targeting mechanism as payload-containing counterparts for accurate control comparisons
Optimized Empty Formulation: SM102-based ionizable lipid system maintaining delivery characteristics without cargo
Covalent Conjugation: Stable antibody-lipid conjugation ensuring consistent targeting performance
Ready-to-Use Control: Premade formulation eliminates preparation variability in control experiments
Batch-Specific Documentation: Quality-controlled manufacturing with detailed batch characterization

Applications

Negative control for targeted mRNA delivery experiments
Baseline cytotoxicity and biocompatibility assessment
Cell targeting specificity validation studies
Background signal determination in imaging studies
Control for flow cytometry-based delivery assays
Formulation development and optimization studies
Safety profiling of targeting delivery systems
Training and educational applications in targeted delivery research
Vehicle control for therapeutic payload studies

Product Specifications

Parameter	Specification
Payload	Empty (no cargo)
Conjugated Antibody	CD34 mAb
Ionizable Lipid	SM102
Formulation Components	Ionizable lipid, DSPC, PEG-2000 DMG, Cholesterol
Storage Buffer	10% Sucrose in TBS
Appearance	Clear and colorless
Concentration	Batch specific (~5 mM total lipid)
Availability	On-demand

Storage & Handling Instructions

Storage Temperature: Store at 4°C immediately upon receipt

Shipping: Product is shipped on ice packs to maintain cold chain integrity

Handling Precautions:

Avoid freeze-thaw cycles to maintain nanoparticle integrity
Handle gently to prevent aggregation
Use sterile technique when aliquoting or diluting
Protect from prolonged exposure to room temperature
Keep away from light to preserve mRNA stability

Stability: When stored properly at 4°C, the product maintains stability for 6 months from the date of manufacture. For optimal performance, use within the specified timeframe.

Custom Solutions

At PreciGenome, we understand that research requirements vary. We offer comprehensive customization options for this product:

Alternative Targeting Antibodies: Custom antibody conjugation for different cell surface markers
Payload Modifications: Alternative mRNA sequences, reporters, or therapeutic genes
Formulation Adjustments: Modified lipid compositions or concentrations
Scale Options: Various volume and concentration specifications
Buffer Systems: Alternative storage and working buffers
Bulk Manufacturing: Large-scale production for extensive studies

Our technical team works closely with researchers to develop tailored solutions that meet specific experimental needs and research objectives.

Important Notes

For Research Use Only. This product is not for human or veterinary use.

For technical support, custom formulations, or bulk orders, please contact us.

This product contains genetically modified materials and should be handled according to institutional biosafety guidelines
Performance may vary depending on cell type, experimental conditions, and handling procedures
Optimal transfection conditions should be determined empirically for each specific application
Product specifications are subject to batch-specific variations; refer to individual Certificate of Analysis
Users should validate targeting efficiency and expression levels in their specific experimental systems